GAMMA Investing LLC Has $2.58 Million Position in Royalty Pharma plc (NASDAQ:RPRX)

GAMMA Investing LLC raised its position in Royalty Pharma plc (NASDAQ:RPRX) by 3,146.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,222 shares of the biopharmaceutical company’s stock after acquiring an additional 77,751 shares during the quarter. GAMMA Investing LLC’s holdings in Royalty Pharma were worth $2,577,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its stake in Royalty Pharma by 4.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company’s stock valued at $79,888,000 after acquiring an additional 130,025 shares during the last quarter. Jupiter Asset Management Ltd. acquired a new stake in Royalty Pharma in the fourth quarter valued at $4,950,000. Allspring Global Investments Holdings LLC lifted its stake in Royalty Pharma by 303.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company’s stock valued at $13,926,000 after acquiring an additional 406,123 shares during the last quarter. Truist Financial Corp acquired a new stake in Royalty Pharma in the fourth quarter valued at $371,000. Finally, Vontobel Holding Ltd. acquired a new stake in Royalty Pharma in the fourth quarter valued at $230,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

RPRX has been the subject of a number of recent analyst reports. Wall Street Zen cut shares of Royalty Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, May 20th. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. Finally, Morgan Stanley began coverage on shares of Royalty Pharma in a research report on Friday, May 16th. They issued an “overweight” rating and a $51.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $47.33.

Royalty Pharma Price Performance

Shares of RPRX opened at $35.27 on Friday. The firm has a market capitalization of $19.83 billion, a PE ratio of 24.32, a PEG ratio of 2.31 and a beta of 0.48. The company’s 50-day moving average is $32.74 and its 200-day moving average is $30.86. Royalty Pharma plc has a fifty-two week low of $24.05 and a fifty-two week high of $35.37. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.07. The company had revenue of $839.00 million for the quarter, compared to analyst estimates of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities analysts forecast that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.50%. The ex-dividend date was Friday, May 16th. Royalty Pharma’s payout ratio is presently 47.57%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.